Cellectar Biosciences (CLRB)
(Delayed Data from NSDQ)
$2.20 USD
+0.01 (0.46%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $2.19 -0.01 (-0.45%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth F Momentum F VGM
Brokerage Reports
Cellectar Biosciences, Inc. [CLRB]
Reports for Purchase
Showing records 1 - 20 ( 126 total )
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
2Q24: Latest Pivotal Trial Data Show Iopofosine Potency - Stock Undervalued
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
More Mature Pivotal Trial Data Show Iopofosine Potency - Stock Undervalued
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Collaborating With CoH to Test Iopofosine in Mycosis Fungoides
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
1Q24: Strong Iopofosine Data Underpins 2H24 NDA Filing Sales in 1H25
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
4Q23: With Solid Iopofosine Data, Expecting 2H24 NDA Filing Sales in 1H25
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Impressive Efficacy With Iopofosine In HNSCC In Phase 1 Investigator Trial
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Receives 2nd of 3 Likely Fundings, Iopofosine Usefully Penetrates CNS
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
KOL Call Emphasizes Iopofosine Differentiation and Likely Market Adoption
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Inlicenses TAT Drug Technology, Partners with AON to Promote Iopofosine
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Pivotal Iopofosine Trial Strongly Succeeds, NDA to Be Filed in 2H24
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Expands Iopofosine Collaboration w/WARF, Receives New Patent Allowances
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
3Q23: Awaiting Positive Pivotal Iopofosine Results in WM in January 2024
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Florida Cancer Specialists Research Inst. Deal To Support Iopofosine
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Four Ex-U.S. Patents Granted Covering Entire PDC Platform
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J